BioCryst Pharmaceuticals BCRX Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's deferred tax assets and other non-current assets?
- BioCryst Pharmaceuticals (BCRX) reported deferred tax assets and other non-current assets of $19.7M in Q1 2026.
- How has BioCryst Pharmaceuticals's deferred tax assets and other non-current assets changed year-over-year?
- BioCryst Pharmaceuticals's deferred tax assets and other non-current assets increased by 306.1% year-over-year, from $4.85M to $19.7M.
- What is the long-term trend for BioCryst Pharmaceuticals's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's deferred tax assets and other non-current assets has grown at a 8.3% compound annual growth rate (CAGR), from $3.8M to $5.67M.